Drug Profile
ROSE 010
Alternative Names: GTP-010; LY-307161 SR; ROSE-010Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Rose Pharma
- Class Antihyperglycaemics; Glucagon-like peptides; Peptides
- Mechanism of Action Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyspepsia; Irritable bowel syndrome; Type 2 diabetes mellitus
Most Recent Events
- 22 Oct 2008 Efficacy and adverse events data from a phase IIa trial in Irritable bowel syndrome presented at the 16th United European Gastroenterology Week (UEGW-2008)
- 22 May 2008 Final efficacy data from a phase II trial in Irritable bowel syndrome presented at Digestive Disease Week 2008 (DDW-2008)
- 13 Oct 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (SC)